Table 5.

The Polymorphisms of the GEMIN4 Gene and the Risk of Prostate Cancer in Different clinical Stages

		Controls (N=244)	Clinical stage I and II (N=81)		Clinical stage III and IV (N=219)		Clinical stage III and IV vs. Clinical stage I and II
Polymorphism	Genotype and allele	n	n	OR	n	OR	OR
	CC	19	3	1	7	1	1
	CT	81	26	2.03 (0.53, 11.52)	72	2.41 (0.90, 7.17)	1.19 (0.18, 5.68)
	TT	144	52	2.29 (0.63, 12.52)	140	2.64 (1.02, 7.64)	1.15 (0.19, 5.28)
	C	119	32	1	86	1	1
rs7813	T	369	130	1.31 (0.83, 2.10)	352	1.32 (0.95, 1.83)	1.01 (0.62, 1.61)
	TT	201	73	1	186	1	1
	TA/AA	43	8	0.51 (0.20, 1.17)	33	0.83 (0.49, 1.40)	1.62 (0.69, 4.25)
	T	445	154	1	405	1	1
rs4968104	A	43	8	0.54 (0.21, 1.19)	33	0.84 (0.51, 1.39)	1.57 (0.69, 4.02)
	CC	142	41	1	147	1	1
	CT	82	30	1.27 (0.71, 2.26)	62	0.73 (0.48, 1.11)	0.58 (0.32, 1.05)
	TT	20	10	1.73 (0.67, 4.24)	10	0.48 (0.20, 1.13)	0.28 (0.10, 0.81)
	C	366	112	1	356	1	1
rs3744741	T	122	50	1.34 (0.88, 2.01)	82	0.69 (0.50, 0.96)	0.52 (0.34, 0.80)
	GG	182	70	1	176	1	1
	GC/CC	62	11	0.46 (0.21, 0.95)	43	0.72 (0.50, 1.14)	1.55 (0.73, 3.54)
	G	426	151	1	395	1	1
rs2740348	C	62	11	0.50 (0.23, 0.99)	43	0.75 (0.48, 1.15)	1.55 (0.73, 3.54)
	TT	240	81	1	217	1	1
	TC/CC	4	0	-	2	0.55 (0.05, 3.91)	-
	T	484	162	-	436	1	1
rs1062923	C	4	0	-	2	0.56 (0.05, 3.90)	-
	CC	18	9	1	14	1	1
	CG	103	32	0.62 (0.24, 1.74)	103	1.29 (0.57, 2.95)	2.07 (0.72, 5.69)
	GG	123	40	0.65 (0.25, 1.78)	102	1.07 (0.47, 2.44)	1.64 (0.58, 4.44)
	C	139	50	1	131	1	1
rs910925	G	349	112	0.89 (0.60, 1.34)	307	0.93 (0.70, 1.25)	1.05 (0.69, 1.57)
	CC	190	65	1	175	1	1
	CT/TT	54	16	0.87 (0.43, 1.67)	44	0.88 (0.55, 1.42)	1.02 (0.52, 2.08)
	C	434	146	1	394	1	1
rs910924	T	54	16	0.88 (0.46, 1.62)	44	0.90 (0.57, 1.40)	1.02 (0.54, 2.00)

The bold numbers mean the p-value is <0.05.